27

Industry News

The Industry News section is a platform for all CIRSE's industry partners, providing them with the opportunity to publicise current news or recent press release material. To make use of this service, please get in touch with Rudi Glock or Marela Rosenzweig at marketing@cirse.org.
 
These industry news items below do not reflect the opinion of CIRSE, nor do they engage its responsibility.
 
 
August 2016
Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced that it has received CE Mark approval and is launching limited commercial sale of its Surfacer® Inside-Out® Access Catheter System. The Surfacer System is indicated for obtaining central venous access to facilitate catheter insertion into the central venous system via a novel Inside-Out approach.
 
 
July, 2016
New data presented by Prof. Dr. Volker Heinemann in an oral abstract session at the European Society of Medical Oncology’s 18th World Congress on Gastrointestinal Cancer suggest that patients with liver-dominant mCRC treated first-line with the combination of mFOLFOX6 and SIR-Spheres Y-90 resin microspheres in the recently published SIRFLOX study experienced a much more profound response to treatment in the liver than those who received chemotherapy alone.1
 
 
June 2016
Results of Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) Randomised Controlled Study Comparing Sorafenib and 
SIR-Spheres® Y-90 resin microspheres in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) Expected in 2017
 
 
May 2016
BTG plc, a specialist healthcare company, announced that it has entered into an agreement to acquire Galil Medical, a leading provider of cryoablation products for the treatment and palliative care of kidney and other cancers.
 
 
April 2016
Abbott and St. Jude Medical, Inc. announced a definitive agreement for Abbott to acquire St. Jude Medical, creating a premier medical device leader with top positions in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure as well as a leading position in the high-growth neuromodulation market. 
 
 
April 2016
Sirtex announced today that the UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing (MIB) stating that NHS doctors and commissioners may consider SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer (hepatocellular carcinoma or HCC).
 
 
March 2016
Sirtex (ASX:SRX) announced that the Netherlands Healthcare Institute, Zorginstituut Nederland (ZIN), has agreed to reimburse Selective Internal Radiation Therapy (SIRT) for patients with colorectal liver metastases who have failed on or are intolerant to prior chemotherapy. The ZIN based its decision on clinical evidence of the efficacy and safety of SIR-Spheres® Y-90 resin microspheres for treating this patient group.
 
 
March 2016
Palliative Group of SORAMIC Study on Treatment of Locally Advanced Primary Liver Cancer with SIR-Spheres® Y-90 resin microspheres followed by Sorafenib Reaches 420-patient Enrolment Target
 
 
February 2016
Sirtex Medical Limited announced that the results of the SIRFLOX study with SIR-Spheres Y-90 resin microspheres have been published on-line in the Journal of Clinical Oncology (JCO), the leading peer-reviewed publication of the American Society of Clinical Oncology (ASCO).
 
 
September 2015
Terumo Corporation and Quirem Medical B.V., a commercial stage Dutch medical technology company that focuses on radioembolization, today announced that Terumo has made an equity investments in Quirem Medical.
 
 
September 2015
Dr Gerard O’Sullivan announced preliminary results from a European study of venous stents today at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015, a European meeting for interventional radiologists and vascular specialists. Dr O’Sullivan is the principal investigator of the VIVO-EU study at the University Hospital Galway.
 
 
September 2015
Dr. Kimihiko Kichikawa, Department of Radiology at Nara Medical University in Japan, reported two-year results of the Zilver® PTX® post-market surveillance (PMS) study on September 27, 2015, in Lisbon, Portugal. Dr. Kichikawa presented initial target data on lesion revascularization (TLR) at Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015, a European meeting for interventional radiologists and vascular specialists.
 
 
September 2015
BTG plc company (LSE: BTG), announced promising data today for DC BeadM1™, supporting the efficacy and tolerability of doxorubicin-eluting DC BeadM1™ in the treatment of patients diagnosed with liver-confined HCC (hepatocellular carcinoma). The preliminary results of the study, in which patients achieved a median overall survival (OS) of 41 months, were presented during the 2015 CIRSE (Cardiovascular and Interventional Radiological Society of Europe) International Conference in Lisbon, Portugal.
 
 
September 2015
CE Mark has been awarded to the new rotating thumbwheel deployment system for Cook Medical’s Zilver® PTX® drug-eluting peripheral stent. The new system, which is now available for purchase in the UK, Ireland, Germany, Spain and Italy, provides simple deployment for the world’s first and only approved drug-eluting stent for the superficial femoral artery (SFA).
 
 
September 2015
Surefire Medical has announced the launch of the company's new Precision targeted delivery infusion system for direct-to-tumor embolization procedures. The new technology will be displayed at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015 Scientific Meeting in Lisbon, Portugal, September 26-30, 2015.
 
 
September 2015
St. Jude Medical today announced the European CE Mark approval for the 27mm and 29mm Portico™ Transcatheter Aortic Valve Replacement System. The approval follows previous approvals of the 23mm and 25mm Portico valves, allowing St. Jude Medical to offer physicians an expanded range of fully repositionable, retrievable TAVR valve sizes. The Portico valve accommodates a patient’s native anatomy with diameters ranging from 19 to 27 mm.
 
 
August 2015
SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 ± bevacizumab + selective internal radiation therapy (SIRT) in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment 
 
 
July 2015
Lombard Medical, Inc., a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the acquisition of Silicon Valley-based Altura Medical, a privately-held, venture-backed company that has developed an innovative ultra-low profile endovascular stent graft technology that offers a simple and predictable solution for the treatment of standard AAA anatomies.
 
 
July 2015
Cordis Corporation announced the launch of the new ELITECROSS™ Support Catheter in the United States and OUTBACK® Elite Re-Entry Catheter in the United States, Europe and Japan. This expansion of the CORDIS® Crossing Portfolio for treatment of chronic total occlusions (CTO) further underlines the company’s decade-long commitment to the space. The new products will add to a suite of specialty and workhorse solutions designed to support physicians in crossing the most complex lesions with control and confidence. 
 
 
May 2015
Boston Scientific announced results from the MAJESTIC Trial, which demonstrate a 94.4% primary patency rate at nine months in patients treated with Boston Scientific’s Eluvia™ Drug-Eluting Vascular Stent System*. 
 
 
May 2015
Sirtex Medical Limited is pleased to announce that the American Society for Clinical Oncology (ASCO) has published the SIRFLOX Study Abstract as part of the 2015 Annual Meeting Abstracts.
 
 
May 2015
Philips, together with the University Hospital Ghent, is launching a 3D navigation system  that will extend the range of treatment options for aneurysms while at the same time making the latest treatment methods available to weaker patients. The solution we have now developed in association with the UH Ghent will make it both quicker and easier to maneuver complex stents into position while using 70% less contrast medium.
 
 
April 2015
In the first-line treatment of non-resectable metastatic colorectal cancer:
-SIRFLOX study does not show a statistically significant improvement in overall Progression-Free Survival. 
-SIRFLOX study does show a statistically significant improvement in Progression-Free Survival in the liver.
 
 
March 2015
CE Mark has been awarded to the new rotating thumbwheel deployment system for Cook Medical’s Zilver® PTX® drug-eluting peripheral stent. The new system, which is now available for purchase in the UK, Ireland, Germany, Spain and Italy, provides simple deployment for the world’s first and only approved drug-eluting stent for the superficial femoral artery (SFA).
 
 
February 2015
BSD Medical Corporation, a leading provider of medical systems that utilise heat therapy to treat cancer, have unveiled its new name and corporate identity, Perseon Corporation (Perseon).  The Company’s new name is coupled with a new visual identity, including the new tagline “Science for Humanity.”
 
 
February 2015
Royal Philips has announced that it has completed the acquisition of Volcano Corporation. Volcano’s financial results will be consolidated as part of Philips’ image-guided therapy business group as of February 17, 2015.
 
 
January 2015
Medtronic plc, a global leader in medical technology, services and solutions, has announced that it has successfully completed the previously announced acquisition of Covidien plc. Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc.  
 
 
November 2014
ONCOZENE™ Microspheres have received FDA 510k clearance and represent exciting advances in the technology of Embozene®, providing a platform for future innovations available to Physicians in the United States.
 
 
November 2014
First and Only DES with Novel CoreWire Technology Allows for Thinner, Stronger Struts, Enhanced Deliverability and Radiopacity without Compromising Structural Strength. Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic, Inc. announced CE (Conformité Européene) mark and international launch of the Resolute Onyx(TM) Drug-Eluting Stent (DES). 
 
 
November 2014
Interventional Cardiology and Oncology as well as treatment of Peripheral Artery Disease (PAD) are the three pillars of Terumo Europe Interventional Systems. Until now, PAD treatment and Interventional Oncology were managed as one entity. The specialization of the Interventional Oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market.
 
 
November 2014
The Spectranetics Corporation and Covidien  today announced a definitive agreement under which Spectranetics will acquire Covidien's Stellarex™ drug coated angioplasty balloon (DCB) platform..
 
 
October 2014
TactiCath ablation catheter with contact-force measurement provides physicians with a new option for treating patients with atrial fibrillation. St. Jude Medical, Inc. a global medical device company, announced U.S. Food and Drug Administration (FDA) approval of its TactiCath™ Quartz irrigated ablation catheter, the company’s newest technology that gives physicians a real-time, objective measure of the force that the catheter applies to a patient’s heart wall during an ablation procedure. TactiCath Quartz contact-force technology was designed to provide physicians with more control to modify that force during ablation procedures in order to create more effective lesions for patients being treated for paroxysmal atrial fibrillation (AF). The technology is associated with a reduction in the rate of AF recurrence when optimal treatment measures are used.
 
 
October 2014
Abbott announced that it has entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm disorders in the world. Through this acquisition, Abbott enters the catheter-based electrophysiology market, an approximately $3 billion global market that has been growing annually at double-digit rates.
 
 
October 2014
Success of the Passeo-18 Lux Drug-Releasing Balloon in Treating Peripheral Artery Disease to Be Assessed in Real-World Population. 
 
 
October 2014
C. R. Bard announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix® 035 Drug Coated Balloon (DCB) Catheter for percutaneous transluminal angioplasty (PTA), after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. This approval follows a unanimous favorable recommendation from the FDA’s Circulatory Systems Devices 
 
 
October 2014
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems. In addition, the Boston Scientific ImageReadyTM technology offers the most flexible MRI options, allowing higher energy scan sequences, and featuring a programmable MRI timer designed to improve patient workflow.
 
 
October 2014
Medtronic  announced the U.S. Food and Drug Administration (FDA) approval of its CapSureFix Novus(TM) MRI SureScan® 5076 Lead for use with magnetic resonance imaging (MRI). The lead is approved for MRI scans positioned on any region of the body when paired with a Medtronic dual-chamber MR-conditional pacemaker.
 
 
October 2014
BTG, the specialist healthcare company, announces it will begin selling its drug-eluting bead and embolisation products, DC Bead® and Bead Block®, directly to customers in 11 European countries from 1 April 2015. These products, developed and manufactured by BTG, are currently sold in Europe by the Terumo Corporation under a contract that expires on 31 March 2015.
 
 
September 2014
Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions. W. L. Gore & Associates announced that it has received approval from the US Food & Drug Administration (FDA) to market its GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for vascular bypass in the Superficial Femoral Artery (SFA). The GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface combines Gore’s proprietary heparin surface treatment with the proven performance of the GORE VIABAHN® Endoprosthesis for treatment of Peripheral Vascular Disease (PVD) in the SFA. In the US alone, as many as 12 million people suffer from some form of PVD.
 
 
September 2014
Cordis Corporation announced the launch of its INCRAFT® AAA Stent Graft System (INCRAFT® System), an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdominal aortic aneurysms (AAA). This device is an advancement in the EVAR field and provides a new option for patients and physicians seeking a less invasive treatment approach for AAA.
 
 
September 2014
BTG, the specialist healthcare company and its partner SciClone Pharmaceuticals Inc., a China-focused specialty pharmaceutical company, have announced that the China Food and Drug Administration has approved the registration of DC Bead® for the embolisation of malignant hypervascularised tumours.
 
 
September 2014
Expanded Indication of Microspheres for Embolization of Hepatoma is an industry first.
 
 
August 2014
DFINE, a market leader in the minimally invasive treatment of spinal diseases, today announced that the first patient has been enrolled in the EU-STAR Clinical Trial. The multi-center trial is the first prospective study to evaluate clinical outcomes in patients receiving treatment with the STAR™ Tumor Ablation System for the palliative treatment of metastatic spinal tumors.
 
 
July 2014
Covidien today announced the commercial launch of its next generation Trellis peripheral infusion system at the Society of Vascular Surgeons’ (SVS) 2014 Vascular Annual Meeting in Boston. The system, which is the only pharmacomechanical thrombolysis device that offers isolation of blood clots (thrombus) and targeted lytic delivery, enables physicians to provide focused treatment of blood clots that lead to Post-thrombotic Syndrome (PTS).
 
 
July 2014
Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Ranger Drug-Coated Balloon (DCB) provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.
 
 
July 2014
Cordis Corporation announced today the launch of its SABER™ PTA Dilatation Catheter (“SABER™ Catheter”) for the treatment of patients with Peripheral Arterial Disease (PAD). The SABER™ Catheter is cleared for use and now available in Europe, the United States and Japan. This new CORDIS® product offers outstanding crossability and a comprehensive offering of balloon sizes on the widely-used .018” over-the-wire platform. Physicians can now treat a wider range of PAD patients with a single balloon brand. 
 
 
July 2014
Hansen Medical, Inc. (NASDAQ: HNSN), announced the successful completion of the world's first clinical procedures using the Magellan™ 6Fr Robotic Catheter. Professor Marc Sapoval, MD, PhD and Dr. Olivier Pellerin, MD, MSc treated three patients with the 6Fr catheter over the span of two days at Hôpital Européen Georges Pompidou (APHP). The cases included two Uterine Fibroid Embolizations and a Transarterial Chemoembolization (TACE) procedure for liver metastasis of colon cancer.  The three cases performed last week were the first in a 25 patient study at Pompidou Hospital (APHP) to assess the use of the new Magellan 6FR Robotic Catheter in a variety of embolization procedures.
 
 
June 2014
Philips’ new NeuroSuite consists of a bi-plane interventional X-ray system with a unique combination of two new detectors: Philips’ frontal FD20 detector delivers live 2D and 3D imaging to provide live navigation and immediate therapy feedback. The new smaller, lateral FD15 detector can be positioned beyond the shoulders and very close to the head. This shorter distance and unique combination of detectors provides sharp, full brain imaging at lower X-ray dose and 3D imaging optimized for neuro and spine interventions.
 
 
June 2014
The Destino Twist™ is a steerable guiding sheath that offers a deflectable tip with an ergonomic handle. The Destino Twist™ is the ultimate tool for gaining access to the most difficult to reach sites, while maintaining hemostasis with Oscor SureSeal™ technology. The Destino Twist™ is your one-sheath solution for introduction of all your diagnostic and therapeutic devices! Destino Twist™ is FDA , CE, & Canada cleared. 
 
 
June 2014
Medtronic, Inc. (NYSE: MDT), a global leader in medical technology, services and solutions, and Covidien plc (NYSE: COV), a global healthcare technology and medical supplies provider, today announced that they have entered into a definitive agreement under which Medtronic has agreed to acquire Covidien in a cash-and-stock transaction
 
 
June 2014
Philips today announced the launch of EmboGuide, its latest innovation in interventional oncology, to treat difficult-to-reach tumors or tumors in patients who are deemed unsuitable for surgery. 
 
 
May 2014
Siemens Healthcare has announced that the U.S. Food and Drug Administration (FDA) has cleared the Artis one – an angiography system optimized for broad clinical utilization.
 
 
Boston Scientific Announces Definitive Agreement to Acquire Interventional Division of Bayer AG
May 2014
In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation has entered into a definitive agreement to acquire the Interventional Division of Bayer AG.
 
 
Eurocor Launches APERTUS Aspiration Catheter 
May 2014
Eurocor GmbH, an Opto Circuits group company, today launched its Apertus Aspiration Catheter. The catheter is specifically designed for enhanced fast and accurate thrombus aspiration. 
 
 
Boston Scientific to Acquire IoGyn, Inc.
May 2014
Boston Scientific Corporation has signed a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company.  The transaction is expected to close within days.  
 
 
Angiodroid - ECR 2014: Published Research by Scalise:  "CO2 in Angiography"
May 2014
Angiodroid is a medical technology company with “Angiodroid The CO₂ Injector” the first system 100% digital, automatic, safe and user friendly.
Filippo Scalise, MD Monza Hospital, Italy – published research on CO2 Angiography: The use of carbon dioxide on peripheral Angiography procedures is a common practise for many decades.To date, it has not the proper success, due to the lack of an advanced technology that could support operators during these procedures.
 
 
BTG Becomes a Major Supporter for ESIRonline
May 2014
BTG and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), are pleased to announce that BTG has become a major supporter of ESIRonline, CIRSE’s extensive database of educational materials on interventional radiology.
 
 
Siemens Becomes New CIRSE Corporate Member (page 23)
March 2014
CIRSE is pleased to welcome Siemens to the ranks of its corporate members. Siemens is a global electrical engineering and electronics company.
 

Guerbet and Sirtex to Collaborate on Clinical Studies
March 2014
The two companies will enter into a major clinical studies collaboration in primary and secondary (metastatic) liver cancer. The objective of the collaboration is to examine how Guerbet’s Lipiodol® Ultra Fluid and Sirtex’s SIR-Spheres® microspheres may be combined or sequenced optimally – and further developed.
 

Vidacare Corporation to be acquired by Teleflex
October 2013
Medical device manufacturer Vidacare Corporation of San Antonio, Texas has entered into a merger agreement to be acquired by Teleflex Incorporated.